ImmunoCellular Therapeutics to present ICT-107 clinical data at World Stem Cell Summit

ImmunoCellular Therapeutics, LtdOct 5 2010

ImmunoCellular Therapeutics (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that the company's clinical data from ICT-107 will be featured in two oral sessions at the World Stem Cell Summit, which is being held October 4-6 in Detroit, MI. John Yu, MD, ImmunoCellular's chief scientific officer and director of surgical neuro-oncology at Cedars-Sinai Medical Center in Los Angeles will present at two sessions :

“The previously presented impressive survival and safety outcomes we have seen with ICT-107 in glioblastoma patients underscore the potential of cancer stem cell-targeting therapies to improve treatment standards for even the most aggressive of cancers”

• Stem Cell Progress Report - ALS, Parkinson's and Other Neurological Diseases

October 5, 2010, 2:30-3:30 p.m. EST

• Hospital Perspectives on Stem Cells and Regenerative Medicine

October 5, 2010, 3:30-4:30 p.m. EST

In the first session, Dr. Yu will discuss the results of a Phase I study of ICT-107, the company's lead cancer stem cell-targeting vaccine for the treatment of glioblastoma multiforme (GBM). The second session, in which Dr. Yu will also participate, will highlight the relationship between ImmunoCellular and Cedars-Sinai as an example of how industry and academia are working together to produce breakthroughs in stem cell research.

"The previously presented impressive survival and safety outcomes we have seen with ICT-107 in glioblastoma patients underscore the potential of cancer stem cell-targeting therapies to improve treatment standards for even the most aggressive of cancers," said Dr. Manish Singh, President and CEO of ImmunoCellular Therapeutics. "Industry partnerships with leading institutions such as Cedars-Sinai play a key role in our strategy to bring innovative drugs to market in the most efficient way possible. We look forward to continuing to work with Cedars-Sinai on additional studies of ICT-107 and other novel, immune-based technologies developed there, for which we have an exclusive licensing agreement."